Next Article in Journal
Evolution of Patterns of Care and Outcomes in the Real-Life Setting for Patients with Metastatic GIST Treated in Three French Expert Centers over Three Decades
Previous Article in Journal
ACLP Activates Cancer-Associated Fibroblasts and Inhibits CD8+ T-Cell Infiltration in Oral Squamous Cell Carcinoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 15
Issue 17
10.3390/cancers15174305
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Cancer and Pregnancy: Estimates in Italy from Record-Linkage Procedures between Cancer Registries and the Hospital Discharge Database

by
Daniela Pierannunzio
1,
Alice Maraschini
2,
Tania Lopez
1,*,
Serena Donati
1,
Rosalba Amodio
3,
Fortunato Bianconi
4,
Rossella Bruni
5,
Marine Castaing
6,
Claudia Cirilli
7,
Giovanna Fantaci
8,
Linda Guarda
9,
Silvia Iacovacci
10,
Lucia Mangone
11,
Guido Mazzoleni
12,
Walter Mazzucco
3,
Anna Melcarne
13,
Elisabetta Merlo
14,
Fabio Parazzini
15,
Fedro Alessandro Peccatori
16,
Massimo Rugge
17,18,
Giuseppe Sampietro
19,
Giovanni Scambia
20,
Giovanna Scarfone
21,
Ausilia Sferrazza
22,
Fabrizio Stracci
23,
Antonina Torrisi
24,
Maria Francesca Vitale
25 and
Silvia Francisci
1add Show full author list remove Hide full author list
1
National Centre for Disease Prevention and Health Promotion, Italian National Institute of Health, 00162 Rome, Italy
2
Technical-Scientific Statistical Service, Italian National Institute of Health, 00162 Rome, Italy
3
Clinical Epidemiology and Cancer Registry Unit, Azienda Ospedaliera Universitaria Policlinico (AOUP), 90127 Palermo, Italy
4
Area Operativa ICT—PuntoZero Scarl, 06128 Perugia, Italy
5
AReSS Puglia, 70121 Bari, Italy
6
Siracusa Cancer Registry, Health Unit of Siracusa, 96100 Siracusa, Italy
7
Dipartimento di Epidemiologia e Comunicazione del Rischio, AUSL di Modena, 41126 Modena, Italy
8
UOS Registro Tumori ASP Trapani, 91100 Trapani, Italy
9
SC Osservatorio Epidemiologico ATS Valpadana, 46100 Mantova, Italy
10
RT LT, Dipartimento di Prevenzione ASL Latina, 04100 Latina, Italy
11
European Epidemiology Unit, Gynecologic Oncology Department, AUSL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy
12
Tumor Register South Tyrol, 39100 Bolzano, Italy
13
Registro Tumori ASL di Lecce, 73100 Lecce, Italy
14
UOC Epidemiologia, Agenzia per la Tutela della Salute (ATS) della Brianza, 20900 Monza, Italy
15
Dipartimento di Scienze Cliniche e di Comunità, Università degli Studi di Milano, 20122 Milano, Italy
16
Gynecologic Oncology Department, European Institute of Oncology IRCCS, 20141 Milan, Italy
17
Surgical Pathology & Cytopathology Unit, Department of Medicine (DIMED), University of Padova, 35128 Padova, Italy
18
Veneto Tumor Registry (RTV), Veneto Regional Authority, 35132 Padova, Italy
19
Health Protection Agency of Bergamo (ATS Bergamo), 24121 Bergamo, Italy
20
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica Roma, 00168 Roma, Italy
21
Gynecologic Oncology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, 20122 Milano, Italy
22
ASP Ragusa-Dipartimento Medico di Prevenzione, UOSD Registro Tumori, 97100 Ragusa, Italy
23
Associazione Nazionale dei Registri Tumori—AIRTUM—Public Health Section, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy
24
Registro Tumori Integrato, Azienda Ospedaliero Universitaria Policlinico “G. Rodolico—San Marco”, 95123 Catania, Italy
25
Napoli 3 Sud Cancer Registry, 80031 Brusciano, Italy
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
Cancers 2023, 15(17), 4305; https://doi.org/10.3390/cancers15174305
Submission received: 15 June 2023 / Revised: 21 August 2023 / Accepted: 24 August 2023 / Published: 28 August 2023
(This article belongs to the Topic Diagnosis, Management, and Prognostic Assessment of Chronic Disease)
Browse Figures
Review Reports Versions Notes

Abstract

:

Simple Summary

Concurrence of pregnancy and cancer diagnosis is an uncommon but not rare event: about 1 pregnancy-associated cancer (PAC) out of 1000 pregnancies is the estimation currently available. This frequency is growing due to postponing childbearing to age groups more at risk of cancer. Interest in this topic is both epidemiological and clinical: improvement of diagnostic and therapeutic techniques makes management of cancer increasingly compatible with pregnancy. The occurrence of PAC challenges women and clinicians who need to manage the two events, safeguarding fetal outcomes without changing the maternal prognosis. This retrospective study aims to provide estimates for PAC and its time trend in Italy by analyzing cross-referenced data from population-based cancer registries and hospital discharges. The proposed methodology is applicable to other populations with available data from Cancer Registries linkable at an individual level with hospitalizations.

Abstract

The aim of this study is to describe the frequency and trend of pregnancy-associated cancer (PAC) in Italy, an increasingly relevant phenomenon due to postponing age at childbirth. To this purpose, a population-based retrospective longitudinal study design based on cohorts of women aged 15–49 diagnosed with cancer and concomitant pregnancy is proposed. The study uses 19 population-based Cancer Registries, covering about 22% of Italy, and linked at an individual level with Hospital Discharge Records. A total of 2,861,437 pregnancies and 3559 PAC are identified from 74,165 women of the cohort with a rate of 1.24 PAC per 1000 pregnancies. The most frequent cancer site is breast (24.3%), followed by thyroid (23.9%) and melanoma (14.3%). The most frequent outcome is delivery (53.1%), followed by voluntary termination of pregnancy and spontaneous abortion (both 12.0%). The trend of PAC increased from 2003 to 2015, especially when the outcome is delivery, thus confirming a new attitude of clinicians to manage cancer throughout pregnancy. This represents the first attempt in Italy to describe PAC from Cancer Registries data; the methodology is applicable to other areas with the same data availability. Evidence from this study is addressed to clinicians for improving clinical management of women with PAC.

1. Introduction

Due to the postponing of parenthood and the increase in maternal age at birth, the frequency of pregnant women with cancer diagnoses has been rising in recent decades [1]. Cancer and pregnancy concurrence is challenging for clinicians required to preserve mother and fetal health, for women who need to be supported facing two crucial events simultaneously, and for epidemiologists aiming at measuring and describing this infrequent and increasingly relevant phenomenon.
For many years, oncological treatments were considered incompatible with pregnancy, and induced abortion or preterm labor were the only options to avoid the delay of cancer treatments. To date, the available evidence shows that it is often possible to safeguard fetal outcomes without changing the maternal prognosis [2,3].
International literature investigating the occurrence of Pregnancy-Associated Cancer (PAC) varies according to the following aspects: (1) the clinical versus the population-based perspective [4,5]; (2) the type of data sources available to measure and monitor PAC, i.e., population-based registries (cancer registries and/or birth registries), hospital discharges, clinical records [6,7,8]; (3) the definition used for PAC, in particular, the event under study (only pregnancy or also its outcomes) [9,10] and (4) the length of the time window used to identify PAC (i.e., the number of months preceding and/or following pregnancy or cancer diagnosis) [4]. A complete overview is available in a recent systematic review [11].
The most common way to measure the frequency of PAC is in terms of a ratio of the number of cancers during pregnancy to the total number of pregnancies. About one PAC every 1000 pregnancies or pregnancy outcomes is the average value estimated among different studies, corresponding to about 8 cancer cases yearly per 100,000, thus indicating an event not frequent but still above the threshold used to identify rare cancers (defined as those with an annual incidence of less than six per 100,000 people in Europe) [12].
North European countries, together with the USA and Australia, count on a tradition in epidemiological studies related to this topic [6,10,13]: there was an increasing trend in the rate of PAC in these areas. A recent Swedish study using cancer registry data linked with hospital discharges reported that cutaneous malignant melanoma, breast, cervical, thyroid, and central nervous system were the most common sites of PAC during 1970–2018 [14].
Few studies come from Southern Europe. Clinician groups led population-based studies in Italy, identifying PAC through Hospital Discharge Records [8,15,16]. They measured a PAC frequency between 127.1 and 134.1 per 100,000 pregnancies; no trend in risk was observed within the calendar year.
The present study aims to measure and describe the frequency as well as the time trend of PAC according to the possible outcomes of pregnancy in Italy using population-based Cancer Registries linked to the individual level of Hospital Discharge Records.

2. Materials and Methods

A longitudinal retrospective study on cohorts of women of childbearing age (15–49 years) was carried out. It was a population-based study where the referring population was constituted by newly cancers’ diagnosed women. Incident cancers were identified by the Cancer Registries and linked with the Hospital Discharge Records using an anonymized unique identification code.
Cancer Registries collect data on all cancer diagnoses occurring in every person residing in the area covered by cancer registration. In this study, the following information for each patient is provided: date of birth, date of diagnosis, gender, vital status, site of primary tumor, and morphology code. The data from population-based Cancer Registries are the basis for the estimation of the cancer burden and its trends over time and are crucial in the planning and evaluation of cancer control programs in the area of registration [17].
According to their data availability, 19 Cancer Registries participating in the study provided incidence cases in 2003–2015; a minimum of five years of incidence was required to participate. We included all women aged 15–49 years diagnosed with malignant cancer (all sites) between 2003 and 2015 in the populations covered by the 19 Cancer Registries participating in the study. We excluded benign, uncertain, and non-melanoma skin cancer.
All malignant cancers, excluding non-melanoma skin cancer, were analyzed with site and morphology coded according to the ICDO-3 classification (C00–C97 excluding C44 with morphology different from 8720–8790). In the case of multiple cancers, the earliest diagnosis was used in the analyses.
Hospital Discharge Records contain information at individual level from hospitals; each record refers to a single hospital admission and includes demographic information (date of birth, sex, place of birth, place of residence), clinical information (main discharge diagnosis and up to five secondary discharge diagnoses, main intervention/procedure and up to five secondary interventions/procedures coded according to International Classification of Diseases, 9th revision, Clinical Modification—ICD9-CM) and administrative information (coded according to the Diagnosis Related Groups—DRG coding system and dates of admission and discharge).
In order to identify PAC, obstetric hospitalizations occurring to women of the study cohorts in the period spanning from one year before to two years after the cancer diagnosis were selected.
Obstetric hospitalizations are selected according to specific diagnostic and procedural codes (the full list of codes is reported in Appendix A). Sequences of similar obstetric events in the same woman are classified according to the final outcome in the following categories: miscarriage, voluntary termination of pregnancy, ectopic pregnancy, hydatidiform mole and birth. About 21% of obstetric hospitalizations cannot be classified according to a specific reproductive outcome and are categorized in a residual group as “other”.
Data at discharge is used as data of the obstetric event.
In order to identify the number of pregnancies, obstetric hospitalizations occurring in the same reference territories of the participating Cancer Registries and in the same years of incidence were selected; in case of multiple hospitalizations referred to the same woman and leading to one of the above-classified outcomes, she counts once.
Hospital Discharge Records do not include home births, but between 2006 and 2015, the average proportion of home births reported by the National Birth Register was 0.1%, a percentage that we consider negligible in terms of risk of underestimation [18].
Time trends of PAC by pregnancy outcome in 2003–2015 were investigated by log-linear models; possible significant changes, expressed as annual percentage changes, were assessed by the permutation test using the JoinPoint Regression Program [19].
The Istituto Superiore di Sanità (Italian National Institute of Health—ISS), in collaboration with the Italian Society of Gynaecology and Obstetrics (SIGO) and the Italian Cancer Registries Association (AIRTUM), coordinated the study.
The Ethics Committee of the ISS approved the protocol of the study.

3. Results

The 19 Cancer Registries involved in the study are located in the North (8), Centre (2), and South (9) of Italy, covering, on average, about 3 million women of childbearing age every year, generally representing 22.6% (ranging from a minimum of 18.7 in 2003 to a maximum of 25.8 in 2010) of the Italian female population aged 15–49; participating Cancer Registries and years of incidence are reported in Appendix B.
A total of 74,165 women aged 15–49 years were diagnosed with malignant cancer (all sites excluding non-melanoma skin cancer) between 2003 and 2015 (Table 1); 1329 (1.8%) had two or more cancers over the study period. Overall, 2,861,437 pregnancies were registered in the Hospital Discharge Records in 2003–2015 in the general female population aged 15–49 years. A total of 4657 obstetric hospitalizations occurred within the time window from one year before to two years after the cancer diagnosis, corresponding to 3559 women with PAC.
Among the 74,165 women aged 15–49 diagnosed with malignant cancer in 2003–2015 (Table 2), the most frequent cancer sites were breast (41.3%), thyroid and other endocrine glands (15.8%), and female genital organs (10.3%), with a median age at diagnosis of 43 years. Among the 3559 women with PAC, breast cancer ranked first (24.3%), followed by the thyroid and other endocrine glands (23.9%) and melanoma of the skin (14.3%), with a median age at diagnosis of 35 years. The last column of the table reports the p-value testing the difference in the two population proportions (women with cancer and women with PAC).
Obstetric hospitalizations were more common before cancer diagnosis (55%), and a peak in the number of obstetric admissions was registered in coincidence with diagnosis: 11.9% within 30 days of the day of diagnosis. (Figure 1).
Over the entire period, for all cancers combined, the most frequent pregnancy outcome was birth (53%), followed by miscarriage (12%) and voluntary termination of pregnancy (12%) (Table 3). Birth, miscarriage, and ectopic pregnancy sharply fell the first year after diagnosis, while voluntary termination of pregnancy had a similar rate one year before and one year after diagnosis. Voluntary termination of pregnancy was most frequent one year before for all cancers and breast cancer and one year after thyroid diagnosis. For breast cancer, a significant reduction in all pregnancy outcomes, except ectopic pregnancy, was observed two years after diagnosis; in the same temporal window, obstetric events markedly rise when referred to thyroid diagnosis.
More than 20% of obstetric hospitalizations are in the category “other”.
Time trends of PAC by pregnancy outcome from 2003 to 2015 showed an increase in births and miscarriages and a decrease in voluntary termination of pregnancy (Figure 2). These trends were confirmed by the Joinpoint regression: for births, the annual percentage change was +7.8 in 2003–2015 (p < 0.05); for miscarriages the annual percentage change was +8.6 in 2003–2015 (p < 0.05) and for voluntary termination of pregnancy the annual percentage change was +2.2 up to 2012, and 18.8 thereafter (annual percentage change values not statistically significant); time trend of PAC for all outcomes combined was increasing with an annual percentage change value of 6.1 (p < 0.05).
On average, in the time period 2003–2015, the age trend of PAC for births increased sharply with age up to 30–34 years, remained almost stable at 35–39, and declined abruptly thereafter; for abortions and voluntary termination of pregnancy increased up to the age 35–39 age group and decreased thereafter (Figure 3).

4. Discussion

Pregnancy-associated cancer is an uncommon event, very challenging for patients and clinicians. It requires early recognition and treatment, taking into account not only maternal health but also fetal safety. Pregnancy complicated by cancers should, therefore, always be referred to facilities with high-risk maternity units and multidisciplinary teams to favor the optimal diagnostic and therapeutic approach. Proper investigation of an underlying malignancy during pregnancy may be delayed due to pregnancy physiological changes that can affect pharmacokinetic parameters and possibly impact the effectiveness and security of pharmacological therapy [20,21,22,23,24]. According to the International Network on Cancer, Infertility and Pregnancy (INCIP) Registry data, iatrogenic preterm birth induced for maternal oncological reasons, rather than chemotherapy exposure, was the main cause of early postnatal complications and poor neonatal neurodevelopmental outcomes [5].
Despite the need for epidemiological data supporting clinical practice, uncertainties remain about the frequency and time trends of PAC.
Our study contributes to the field by providing recent estimates and trends of the rate of PAC in Italy based on Cancer Registries data individually linked with Hospital Discharge Records, thus considering cancer diagnosis as a reference event and tracing obstetric hospitalizations one year before and two years after the cancer diagnosis in order to identify PAC.
The reason for selecting obstetric events up to one year before the cancer diagnosis, instead of 9 months, is related to the evidence that in clinical practice, the date of cancer diagnosis represents the end of a clinical path, with diagnostic tests carried out up to 12 months before the diagnosis is registered. Concerning the choice of considering two years after a cancer diagnosis, this seems reasonable for finalizing surgery and other first-course therapies.
The study found an overall rate of PAC of 1.24 per 1000 pregnancies, consistent with the literature as reported in a recent systematic review, with an average value of 1.09 PAC per 1000 pregnancies [11] and in other Italian studies reporting 1.34 PAC per 1000 pregnancies [8].
The increasing trend of the rate of PAC is also confirmed by other international studies [6,10,13].
Our study showed an increase in the rate of PAC for birth and miscarriage and a decrease in voluntary termination of pregnancy, thus confirming the current attitude to manage pregnancy and oncological treatment, and voluntary termination of pregnancy not being considered as the only option [7,25,26].
PAC were more frequent in the case of cancers of the breast, thyroid, and other endocrine glands; as concerning breast cancer, our finding is consistent with the literature, as concerning thyroid cancer, the high frequency is probably related to the diagnostic pressure in Italy [27]. Differences in the cancer ranking concerning the general female population aged 15–49 were also due to the different age composition of the two groups (women with PAC are younger); melanoma was the third cancer in the general female population, while it was the fifth among women with PAC [28].
Results by reproductive outcome differ by cancer site: with respect to all cancers, miscarriage and voluntary termination of pregnancy occurred more often in the case of breast cancer and birth in the case of thyroid cancer; this difference is probably related to the prognosis of these cancers and consequently less aggressive therapies. The study reported a peak in the number of obstetric admissions at the time of cancer diagnosis, probably due to the intensification of clinical monitoring for women facing a cancer diagnosis during pregnancy. Obstetric events 2 years after cancer diagnosis had a lower level, and the reduction was probably due to the women’s refusal to start pregnancy during or immediately after cancer treatments. On the other side, this period could be worthy of further investigation on fertility. The relation among pregnancy outcomes, cancer site, and distance from diagnosis could provide additional evidence for clinicians [29,30]. Additionally, a recent study reported that the timing of diagnosis impacts the clinical cancer characteristics, e.g., for breast cancer, thus influencing the therapeutic approach and survival at 5–10 years from pregnancy [31].
Younger women experience miscarriage and voluntary termination of pregnancy less frequently than women aged 35 years and over. The highest percentage of births detected among women aged 30–34 years is coherent with the Italian mean age at birth [18].
The most relevant strength of this study is the use of Cancer Registries’ to identify cancers. Cancer Registries ensure a high level of accuracy and completeness in case identification of detailed and reliable clinical information, thus allowing overcoming methodological limits related to the use of administrative health data only, as is the case for Hospital Discharge databases [32].
A second strength is the population coverage of Cancer Registries’ data, which guarantees that results refer to the whole population rather than to a clinically selected cohort. Moreover, our study design and methodology are applicable to other areas where Cancer Registries and Hospital Discharge Records are available.
The main limitation of our study is related to the data availability and update: Hospital Discharge Records can be considered reliable and available at the national level starting from 2003, and Cancer Registries collect incidence retrospectively with an average delay of three years. Although not representative of Italy, the study cohort covers a high percentage of the national population, about 22%.
Obstetric events not leading to hospitalization do not contribute to the identification of pregnancies in women with cancer, thus implying an underreporting of PAC in our results. The impact of this error seems negligible, given the consistency of our estimates with those reported in other cited studies based on data from surveillance systems of pregnancies and the low frequency of obstetric events managed in ambulatory only.
Another limitation is the lack of high-resolution clinical variables, such as the TNM stage; this variable is not routinely collected by Cancer Registries but can be provided for a subset of patients, as is the case for women with PAC. As further development would be interesting to describe PAC by outcome and stage at diagnosis. In order to describe the clinical pathways for women with PAC, it would be necessary to integrate our dataset with information on outpatient healthcare services and drug use. In addition, it would be worth integrating more information on pregnancy (e.g., gestational age, relevant to estimate maternal survival and infant mortality [33]), delivery, and parental characteristics from the Certificate of Delivery Care Registry (CEDAP).

5. Conclusions

This study represents the first attempt in Italy to provide population-based estimates of pregnancies in women with cancer diagnosis by linking data from Cancer Registries with Hospital Discharge Records at an individual level.
The findings of this study are directed at epidemiologists to measure the phenomenon and to clinicians to raise their awareness of the potential to treat cancer during pregnancy, of the need to properly counsel future parents confronted with a cancer diagnosis during pregnancy, and of the necessity to always consider referral to health facilities with knowledge and awareness about cancer treatment during pregnancy. Additionally, the methodology can be used in other regions or countries where Cancer Registries and Hospital Discharge Records data are available. A further direction of study could aim at producing evidence about survival perspectives for women with PAC.

Author Contributions

Conceptualization, D.P., A.M. (Alice Maraschini), T.L., S.D. and S.F.; data curation, R.A., Fortunato Bianconi, R.B., M.C., C.C., G.F., L.G., S.I., L.M., G.M., W.M., A.M. (Anna Melcarne), E.M., M.R., G.S. (Giuseppe Sampietro), A.S., F.S. and M.F.V.; formal analysis, D.P. and A.M. (Alice Maraschini); funding acquisition, D.P. and A.M. (Alice Maraschini); methodology, D.P., A.M. (Alice Maraschini) and T.L.; validation, R.A., F.B., R.B., M.C., C.C., G.F., L.G., S.I., L.M., G.M., W.M., A.M. (Anna Melcarne), E.M., F.P., F.A.P., M.R., G.S. (Giuseppe Sampietro), G.S. (Giovanni Scambia), G.S. (Giovanna Scarfone), A.S., F.S., A.T. and M.F.V.; writing—original draft, D.P., A.M. (Alice Maraschini), T.L., S.D. and S.F.; writing—review and editing, D.P., T.L., S.D. and S.F. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by the Italian National Institute of Health (Bando Ricerca Indipendente ISS 2020–2022), project code ISS20-a4627f16ba39.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Italian National Institute of Health (Protocol code AOO-ISS 0028471, 26 September 2018).

Informed Consent Statement

The Italian legislation identifies regional and national health authorities as collectors of personal data for surveillance purposes without explicit individual consent. This study is a descriptive analysis of anonymous aggregate data without any direct or indirect intervention on patients (Decreto del Presidente del Consiglio dei Ministri, 3 March 2017, Identificazione dei sistemi di sorveglianza e dei registri di mortalità, di tumori e di altre patologie, 17A03142, GU Serie Generale n.109 del 12-05-2017). Available at: www.gazzettaufficiale.it/eli/id/2017/05/12/17A03142/sg (accessed on 9 March 2023).

Data Availability Statement

Data are unavailable due to privacy restrictions.

Acknowledgments

The authors thank Monica Pirri for administrative support, Letizia Sampaolo for support in bibliographic research, Silvia Andreozzi for graphics support, and Marco Salvatore for text review.

Conflicts of Interest

The authors declare no conflict of interest.

Appendix A

Table A1. Codes used for obstetric hospitalizations selection.
Table A1. Codes used for obstetric hospitalizations selection.
Hospital Discharge Records Are Selected If They Contain at Least One of the Following Criteria:
ConditionCodeSystem
Complications of Pregnancy, Childbirth, and the Puerperium630–677ICD9-cm principal or secondary diagnosis
Use of health services for pregnancyV22, V23, V24, V27, V28ICD9-cm principal or secondary diagnosis
Livebirth or stillbirthV30–V39ICD9-cm principal or secondary diagnosis
Obstetrical Procedures72–75ICD9-cm principal or secondary procedure
Obstetrical hospitalization370–384Diagnosis Related Groups (DRG)
Dilation and curettage for termination of pregnancy69.01ICD9-cm principal or secondary procedure
Dilation and curettage following delivery or abortion69.02ICD9-cm principal or secondary procedure
Aspiration curettage of uterus for termination of pregnancy69.51ICD9-cm principal or secondary procedure
Aspiration curettage following delivery or abortion69.52ICD9-cm principal or secondary procedure
Salpingectomy with removal of tubal pregnancy66.62ICD9-cm principal or secondary procedure

Appendix B

Participating Cancer Registries and years of incidence.
  • Cancer Registry of Alto Adige (2003–2013)
  • Cancer Registry of Monza-Brianza (2007–2012)
  • Cancer Registry of Cremona (2005–2012)
  • Cancer Registry of Mantova (2003–2014)
  • Cancer Registry of Bergamo (2007–2015)
  • Cancer Registry of Veneto (2003–2015)
  • Cancer Registry of Modena (2003–2015)
  • Cancer Registry of Reggio Emilia (2003–2015)
  • Cancer Registry of ASL Napoli 3 Sud (2003–2015)
  • Cancer Registry of Barletta-Andria-Trani (2006–2014)
  • Cancer Registry of Lecce (2003–2010)
  • Cancer Registry of Catanzaro (2006–2010)
  • Cancer Registry of Messina-Catania-Enna (2003–2015)
  • Cancer Registry of Siracusa (2003–2015)
  • Cancer Registry of Palermo (2003–2015)
  • Cancer Registry of Trapani (2003–2011)
  • Cancer Registry of Ragusa (2003–2014)
  • Cancer Registry of Latina (2009–2013)
  • Cancer Registry of Umbria (2003–2015)

References

  1. Niu, X.; Li, C.I.; Mueller, B.A. Obstetrical and infant outcomes among women with neoplasms during pregnancy. Cancer Causes Control 2019, 30, 651–661. [Google Scholar] [CrossRef]
  2. Pavlidis, N.A. Coexistence of pregnancy and malignancy. Oncologist 2002, 7, 279–287, Erratum in Oncologist 2002, 7, 585. [Google Scholar] [CrossRef]
  3. Salani, R.; Billingsley, C.C.; Crafton, S.M. Cancer and pregnancy: An overview for obstetricians and gynecologists. Am. J. Obstet. Gynecol. 2014, 211, 7–14. [Google Scholar] [CrossRef]
  4. Andersson, T.M.; Johansson, A.L.; Fredriksson, I.; Lambe, M. Cancer during pregnancy and the postpartum period: A population-based study. Cancer 2015, 121, 2072–2077. [Google Scholar] [CrossRef]
  5. De Haan, J.; Verheecke, M.; Van Calsteren, K.; Van Calster, B.; Shmakov, R.G.; Mhallem Gziri, M.; Halaska, M.J.; Fruscio, R.; Lok, C.A.R.; Boere, I.A.; et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: A 20-year international cohort study of 1170 patients. Lancet Oncol. 2018, 19, 337–346, Erratum in Lancet Oncol. 2021, 22, e389. [Google Scholar] [CrossRef]
  6. Lee, Y.Y.; Roberts, C.L.; Dobbins, T.; Stavrou, E.; Black, K.; Morris, J.; Young, J. Incidence and outcomes of pregnancy-associated cancer in Australia, 1994–2008: A population-based linkage study. J. Obstet. Gynaecol. 2012, 119, 1572–1582. [Google Scholar] [CrossRef]
  7. Amant, F.; Vandenbroucke, T.; Verheecke, M.; Fumagalli, M.; Halaska, M.J.; Boere, I.; Han, S.; Gziri, M.M.; Peccatori, F.; Rob, L.; et al. Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. N. Engl. J. Med. 2015, 373, 1824–1834. [Google Scholar] [CrossRef]
  8. Parazzini, F.; Franchi, M.; Tavani, A.; Negri, E.; Peccatori, F.A. Frequency of Pregnancy Related Cancer: A Population Based Linkage Study in Lombardy, Italy. Int. J. Gynecol. Cancer 2017, 27, 613–619. [Google Scholar] [CrossRef]
  9. Metcalfe, A.; Cairncross, Z.F.; Friedenreich, C.M.; Ray, J.G.; Nelson, G.; Fell, D.B.; Lisonkova, S.; Bhatti, P.; McMorris, C.; Sikdar, K.C.; et al. Incidence of Pregnancy-Associated Cancer in Two Canadian Provinces: A Population-Based Study. Int. J. Environ. Res. Public Health 2021, 18, 3100. [Google Scholar] [CrossRef]
  10. Eibye, S.; Kjær, S.K.; Mellemkjær, L. Incidence of pregnancy-associated cancer in Denmark, 1977–2006. Obstet. Gynecol. 2013, 122, 608–617. [Google Scholar] [CrossRef]
  11. Dalmartello, M.; Negri, E.; La Vecchia, C.; Scarfone, G.; Buonomo, B.; Peccatori, F.A.; Parazzini, F. Frequency of Pregnancy-Associated Cancer: A Systematic Review of Population-Based Studies. Cancers 2020, 12, 1356. [Google Scholar] [CrossRef]
  12. Gatta, G.; Capocaccia, R.; Botta, L.; Mallone, S.; De Angelis, R.; Ardanaz, E.; Comber, H.; Dimitrova, N.; Leinonen, M.K.; Siesling, S.; et al. Burden and centralised treatment in Europe of rare tumours: Results of RARECAREnet-a population-based study. Lancet Oncol. 2017, 18, 1022–1039, Erratum in Lancet Oncol. 2017, 18, e433. [Google Scholar] [CrossRef] [PubMed]
  13. Cottreau, C.M.; Dashevsky, I.; Andrade, S.E.; Li, D.K.; Nekhlyudov, L.; Raebel, M.A.; Ritzwoller, D.P.; Partridge, A.H.; Pawloski, P.A.; Toh, S. Pregnancy-Associated Cancer: A U.S. Population-Based Study. J. Women’s Health 2019, 28, 250–257. [Google Scholar] [CrossRef]
  14. Johansson, A.L.V.; Fredriksson, I.; Mellemkjaer, L.; Stensheim, H.; Lähteenmäki, P.; Winther, J.F.; Ullenhag, G.J.; Lundberg, F.E. Cancer survival in women diagnosed with pregnancy-associated cancer: An overview using nationwide registry data in Sweden 1970–2018. Eur. J. Cancer 2021, 155, 106–115. [Google Scholar] [CrossRef] [PubMed]
  15. Murgia, F.; Marinaccio, M.; Cormio, G.; Loizzi, V.; Cicinelli, R.; Bettocchi, S.; Cicinelli, E. Pregnancy related cancer in Apulia. A population based linkage study. Eur. J. Obstet. Gynecol. Reprod. Biol. X 2019, 3, 100025. [Google Scholar] [CrossRef] [PubMed]
  16. Parazzini, F.; Gadducci, A.; Cicinelli, E.; Maggino, T.; Peccatori, F.; Scarfone, G.; Roncella, E.; Scambia, G.; Zola, P.; Sartori, E. Pregnancy-associated cancers: Frequency and temporal trends in Italy. Int. J. Gynecol. Cancer 2020, 30, 241–244. [Google Scholar] [CrossRef]
  17. Guzzinati, S.; Battagello, J.; Bovo, E.; Baracco, M.; Baracco, S.; Carpin, E.; Dal Cin, A.; Fiore, A.R.; Greco, A.; Martin, G.; et al. Quality control on digital cancer registration. PLoS ONE 2022, 17, e0279415. [Google Scholar] [CrossRef]
  18. Certificato di Assistenza al Parto (CeDAP). Analisi dell’Evento Nascita—Anno 2021, A Cura di Direzione Generale della Digitalizzazione, del Sistema Informativo Sanitario e della Statistica—Ufficio di Statistica, Anno 2022. Available online: https://www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?lingua=italiano&id=3264 (accessed on 14 June 2023).
  19. Kim, H.J.; Fay, M.P.; Feuer, E.J.; Midthune, D.N. Permutation tests for joinpoint regression with applications to cancer rates. Stat. Med. 2000, 19, 335–351, Erratum in Stat. Med. 2001, 20, 655. [Google Scholar] [CrossRef]
  20. Linkeviciute, A.; Canario, R.; Peccatori, F.A.; Dierickx, K. Guidelines for Cancer Treatment during Pregnancy: Ethics-Related Content Evolution and Implications for Clinicians. Cancers 2022, 14, 4325. [Google Scholar] [CrossRef]
  21. Galati, F.; Magri, V.; Arias-Cadena, P.A.; Moffa, G.; Rizzo, V.; Pasculli, M.; Botticelli, A.; Pediconi, F. Pregnancy-Associated Breast Cancer: A Diagnostic and Therapeutic Challenge. Diagnostics 2023, 13, 604. [Google Scholar] [CrossRef]
  22. Peccatori, F.A.; Azim, H.A., Jr.; Orecchia, R.; Hoekstra, H.J.; Pavlidis, N.; Kesic, V.; Pentheroudakis, G.; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013, 24 (Suppl. S6), VI160–VI170. [Google Scholar] [CrossRef] [PubMed]
  23. Paris, I.; Di Giorgio, D.; Carbognin, L.; Corrado, G.; Garganese, G.; Franceschini, G.; Sanchez, A.M.; De Vincenzo, R.P.; Accetta, C.; Terribile, D.A.; et al. Pregnancy-Associated Breast Cancer: A Multidisciplinary Approach. Clin. Breast Cancer 2021, 21, e120–e127. [Google Scholar] [CrossRef] [PubMed]
  24. McCormick, A.; Peterson, E. Cancer in Pregnancy. Obstet. Gynecol. Clin. N. Am. 2018, 45, 187–200. [Google Scholar] [CrossRef]
  25. Zemlickis, D.; Lishner, M.; Degendorfer, P.; Panzarella, T.; Burke, B.; Sutcliffe, S.B.; Koren, G. Maternal and fetal outcome after breast cancer in pregnancy. Am. J. Obstet. Gynecol. 1992, 166, 781–787. [Google Scholar] [CrossRef]
  26. Amant, F.; Deckers, S.; Van Calsteren, K.; Loibl, S.; Halaska, M.; Brepoels, L.; Beijnen, J.; Cardoso, F.; Gentilini, O.; Lagae, L.; et al. Breast cancer in pregnancy: Recommendations of an international consensus meeting. Eur. J. Cancer 2010, 46, 3158–3168. [Google Scholar] [CrossRef] [PubMed]
  27. Dal Maso, L.; Panato, C.; De Paoli, A.; Mattioli, V.; Serraino, D.; Elisei, R.; Zoppini, G.; Gobitti, C.; Borsatti, E.; Di Felice, E.; et al. Trends in thyroid function testing, neck ultrasound, thyroid fine needle aspiration, and thyroidectomies in North-eastern Italy. J. Endocrinol. Investig. 2021, 44, 1679–1688. [Google Scholar] [CrossRef]
  28. AIOM. I Numeri del Cancro 2019. Available online: https://www.aiom.it/wp-content/uploads/2019/09/2019_Numeri_Cancro-operatori-web.pdf (accessed on 14 June 2023).
  29. Di Tucci, C.; Galati, G.; Mattei, G.; Chinè, A.; Fracassi, A.; Muzii, L. Fertility after Cancer: Risks and Successes. Cancers 2022, 14, 2500. [Google Scholar] [CrossRef]
  30. Lawrenz, B.; Henes, M.; Neunhoeffer, E.; Fehm, T.; Huebner, S.; Kanz, L.; Marini, P.; Mayer, F. Pregnancy after successful cancer treatment: What needs to be considered? Onkologie 2012, 35, 128–132. [Google Scholar] [CrossRef] [PubMed]
  31. Amant, F.; Lefrère, H.; Borges, V.F.; Cardonick, E.; Lambertini, M.; Loibl, S.; Peccatori, F.; Partridge, A.; Schedin, P. The definition of pregnancy-associated breast cancer is outdated and should no longer be used. Lancet Oncol. 2021, 22, 753–754. [Google Scholar] [CrossRef]
  32. Lee, Y.Y.; Roberts, C.L.; Young, J.; Dobbins, T. Using hospital discharge data to identify incident pregnancy-associated cancers: A validation study. BMC Pregnancy Childbirth 2013, 13, 37. [Google Scholar] [CrossRef]
  33. Lu, D.; Ludvigsson, J.F.; Smedby, K.E.; Fall, K.; Valdimarsdóttir, U.; Cnattingius, S.; Fang, F. Maternal Cancer During Pregnancy and Risks of Stillbirth and Infant Mortality. J. Clin. Oncol. 2017, 35, 1522–1529. [Google Scholar] [CrossRef] [PubMed]
Cancers 15 04305 g001
Figure 1. Distribution of obstetric hospitalizations (N) of women aged 15–49 by distance (in months) from cancer diagnosis: 2003–2015, Italy.
Figure 1. Distribution of obstetric hospitalizations (N) of women aged 15–49 by distance (in months) from cancer diagnosis: 2003–2015, Italy.
Cancers 15 04305 g001
Cancers 15 04305 g002
Figure 2. Time trend 2003–2015 of the rate of PAC (per 1000 pregnancies) among women aged 15–49 by pregnancy outcome: all cancers, Italy, (annual percentage change in box, linear trend in dots). ‘*’ stands for statistically significant APC values (p < 0.05).
Figure 2. Time trend 2003–2015 of the rate of PAC (per 1000 pregnancies) among women aged 15–49 by pregnancy outcome: all cancers, Italy, (annual percentage change in box, linear trend in dots). ‘*’ stands for statistically significant APC values (p < 0.05).
Cancers 15 04305 g002
Cancers 15 04305 g003
Figure 3. Age trend of PAC (%) by pregnancy outcome: all cancers, 2003–2015, Italy.
Figure 3. Age trend of PAC (%) by pregnancy outcome: all cancers, 2003–2015, Italy.
Cancers 15 04305 g003
Table 1. Distribution of women with cancer diagnosis, number of pregnancies, number of women with PAC, and rate of PAC (per 1000 pregnancies) by year of cancer incidence: ages 15–49, all cancers, 2003–2015, Italy.
Table 1. Distribution of women with cancer diagnosis, number of pregnancies, number of women with PAC, and rate of PAC (per 1000 pregnancies) by year of cancer incidence: ages 15–49, all cancers, 2003–2015, Italy.
Year of Cancer IncidenceWomen with Cancer DiagnosisPregnanciesPACPAC/Pregnancies × 1000
20034158221,0372301.04
20044266228,9012100.92
20054488226,9952160.95
20064742238,1922070.87
20075586262,3822701.03
20086306260,3982981.14
20096736264,1713281.24
20106663260,5483301.27
20116166179,6012851.59
20126149169,9222961.74
20136734201,8223281.63
20146393182,4073031.66
20155778165,0612581.56
2003–201574,1652,861,43735591.24
Table 2. Distribution of women aged 15–49 and women with PAC aged 15–49 by cancer type (absolute and percent values): 2003–2015, Italy.
Table 2. Distribution of women aged 15–49 and women with PAC aged 15–49 by cancer type (absolute and percent values): 2003–2015, Italy.
Women
15–49		Women with PAC
15–49
Topography *N%N%p
Breast (C50)30,62641.2986624.330.0000
Thyroid and other endocrine glands (C73–C75)11,73115.8284923.860.0000
Femal genital organs (C51–C58)762610.283509.830.3893
Digestive organs (C15–C26)57557.762125.960.0001
Melanoma of the skin (C44 with morphology codes: 8720–8790)52547.0851014.330.0000
Lymph nodes (C77)29373.962005.620.0000
Hematopoietic and reticuloendothelial systems (C42)28063.781694.750.0034
Respiratory system and intrathoracic organs (C30–C39)22923.09972.730.2179
Eye, brain, and other parts of central nervous system (C69–C72)14081.90982.750.0003
Urinary tract (C64–C68)13611.84852.390.0170
Lip, oral cavity, and pharynx (C00–C14)8761.18411.150.8750
Connective, subcutaneous, and other soft tissues (C49)5030.68350.980.0319
Unknown primary site (C80)3640.49210.590.4100
Bones, joints, and articular cartilage of other and unspecified sites (C40–C41)3010.41150.420.8863
Other and ill-defined sites (C76)1570.2160.170.5829
Retroperitoneum and peritoneum (C48)1360.1840.110.3293
Peripheral nerves and autonomic nervous system (C47)320.0410.030.6703
Total74,165100.003559100.00
* All morphologies were considered except for the Skin (C44), for which only the 8720–8790 codes were included.
Table 3. Distribution of women aged 15–49 with PAC by pregnancy outcome and timing (one year before cancer diagnosis, one year after cancer diagnosis, and two years after cancer diagnosis) for all cancers, breast cancer and thyroid and other endocrine glands cancer, % value (counts): 2003–2015.
Table 3. Distribution of women aged 15–49 with PAC by pregnancy outcome and timing (one year before cancer diagnosis, one year after cancer diagnosis, and two years after cancer diagnosis) for all cancers, breast cancer and thyroid and other endocrine glands cancer, % value (counts): 2003–2015.
All Cancers
Pregnancy OutcomeOne Year before Cancer DiagnosisOne Year after Cancer
Diagnosis		Two Years after
Cancer Diagnosis		Total
Birth59.7 (1477)20.0 (495)20.3 (502)53.1 (2474)
Miscarriage 57.4 (323)19.7 (111)22.9 (129)12.1 (563)
Voluntary termination of pregnancy 45.8 (257)36.0 (202)18.2 (102)12.0 (561)
Ectopic pregnancy and hydatidiform mole63.0 (46)13.7 (10)23.3 (17)1.6 (73)
Pregnancy not classifiable46.2 (456)35.5 (350)18.3 (180)21.2 (986)
Total54.9 (2559)25.1 (1168)20.0 (930)100.0 (4657)
Breast
Pregnancy OutcomeOne Year before Cancer DiagnosisOne Year after
Cancer Diagnosis		Two Years after
Cancer Diagnosis		Total
Birth75.4 (419)21.0 (117)3.6 (20)53.1 (556)
Miscarriage 77.6 (118)17.1 (26)5.3 (8)14.5 (152)
Voluntary termination of pregnancy 61.4 (97)28.5 (45)10.1 (16)15.1 (158)
Ectopic pregnancy and hydatidiform mole63.6 (7)9.1 (1)27.3 (3)1.1 (11)
Pregnancy not classifiable50.6 (86)44.1 (75)5.3 (9)16.2 (170)
Total69.4 (727)25.2 (264)5.4 (56)100.0 (1047)
Thyroid and Other Endocrine Glands Cancer
Pregnancy OutcomeOne Year before
Cancer Diagnosis		One Year after
Cancer Diagnosis		Two Years after
Cancer Diagnosis		Total
Birth52.4 (326)16.9 (105)30.7 (191)56.6 (622)
Miscarriage 45.1 (60)21.8 (29)33.1 (44)12.1 (133)
Voluntary termination of pregnancy 36.3 (58)42.5 (68)21.2 (34)14.6 (160)
Ectopic pregnancy and hydatidiform mole66.7 (6)0.0 (0)33.3 (3)0.8 (9)
Pregnancy not classifiable39.7 (69)24.1 (42)36.2 (63)15.8 (174)
Total47.3 (519)22.2 (244)30.5 (335)100.0 (1098)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Pierannunzio, D.; Maraschini, A.; Lopez, T.; Donati, S.; Amodio, R.; Bianconi, F.; Bruni, R.; Castaing, M.; Cirilli, C.; Fantaci, G.; et al. Cancer and Pregnancy: Estimates in Italy from Record-Linkage Procedures between Cancer Registries and the Hospital Discharge Database. Cancers 2023, 15, 4305. https://doi.org/10.3390/cancers15174305

AMA Style

Pierannunzio D, Maraschini A, Lopez T, Donati S, Amodio R, Bianconi F, Bruni R, Castaing M, Cirilli C, Fantaci G, et al. Cancer and Pregnancy: Estimates in Italy from Record-Linkage Procedures between Cancer Registries and the Hospital Discharge Database. Cancers. 2023; 15(17):4305. https://doi.org/10.3390/cancers15174305

Chicago/Turabian Style

Pierannunzio, Daniela, Alice Maraschini, Tania Lopez, Serena Donati, Rosalba Amodio, Fortunato Bianconi, Rossella Bruni, Marine Castaing, Claudia Cirilli, Giovanna Fantaci, and et al. 2023. "Cancer and Pregnancy: Estimates in Italy from Record-Linkage Procedures between Cancer Registries and the Hospital Discharge Database" Cancers 15, no. 17: 4305. https://doi.org/10.3390/cancers15174305

APA Style

Pierannunzio, D., Maraschini, A., Lopez, T., Donati, S., Amodio, R., Bianconi, F., Bruni, R., Castaing, M., Cirilli, C., Fantaci, G., Guarda, L., Iacovacci, S., Mangone, L., Mazzoleni, G., Mazzucco, W., Melcarne, A., Merlo, E., Parazzini, F., Peccatori, F. A., ... Francisci, S. (2023). Cancer and Pregnancy: Estimates in Italy from Record-Linkage Procedures between Cancer Registries and the Hospital Discharge Database. Cancers, 15(17), 4305. https://doi.org/10.3390/cancers15174305

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop